Drug Profile


Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; CDK 4/6 dual inhibitor - Eli Lilly; Cyclin dependent kinase 4/6 dual inhibitor - Eli Lilly; Cyclin-dependent-kinase-inhibitors-Eli-Lilly; LY-2835219

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Emory University; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin D1 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Non-small cell lung cancer
  • Phase II Cancer; Liposarcoma; Mantle-cell lymphoma
  • Preclinical Solid tumours
  • Phase Unknown Glioblastoma; Pancreatic cancer

Most Recent Events

  • 08 Dec 2016 Final efficacy data from the phase II neoMONARCH trial in Breast cancer (Neoadjuvant therapy) released by Eli Lilly
  • 08 Dec 2016 Eli Lilly completes the phase II neoMONARCH trial for Breast Cancer (Neoadjuvant therapy) in USA, Austria, Belgium, Canada, Germany, Italy, South Korea, Netherlands, Spain and Taiwan
  • 01 Dec 2016 Eli Lilly completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02884089)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top